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Abstract 
Ecotropic viral integration site 1 (Evi1) is a transcription factor that is highly expressed in 
hematopoietic stem cells and is crucial for their self-renewal capacity. Aberrant expression 
of EVI1 is observed in 5% to 10% of patients with de novo acute myeloid leukemia 
(AML) and predicts poor prognosis, reflecting the multiple leukemogenic properties of 
EVI1. Here, I show that thrombopoietin (THPO) signaling is implicated in the growth and 
survival of Evi1-expressing cells, using a mouse model of Evi1 leukemia. I first identified 
that the expression of megakaryocytic surface molecules such as ITGA2B (CD41) and the 
THPO receptor, MPL, positively correlates with EVI1 expression in patients with AML. In 
agreement with this finding, a subpopulation of bone marrow and spleen cells derived 
from Evi1 leukemia mice expressed both CD41 and Mpl. CD41
+
 Evi1 leukemia cells 
induced secondary leukemia more efficiently than CD41
−
 cells in a serial bone marrow 
transplantation assay. Importantly, the CD41
+
 cells predominantly expressing Mpl 
effectively proliferated and survived on OP9 stromal cells in the presence of THPO via 
upregulating BCL-xL expression, suggesting an essential role of the THPO/MPL/BCL-xL 
cascade in enhancing the progression of Evi1 leukemia. These observations provide a 
novel aspect of the diverse functions of Evi1 in leukemogenesis. 
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Introduction 
Acute myeloid leukemia (AML) is a clonal hematological disorder in which somatically 
acquired genetic alterations in hematopoietic stem/progenitor cells (HSPCs) disturb their 
growth and differentiation. Chromosomal abnormalities or specific gene mutations are 
used in the risk classification of AML as prognostic biomarkers. In addition, distinct gene 
expression signatures have been utilized to identify the prognostic subclasses of AML.
1
 
Among these stratified groups, aberrant expression of ecotropic viral integration site 1 
(EVI1) occurs in approximately 5% to 10% of de novo adult AML patients and defines one 
of the largest clusters in AML.
2-5
 EVI1 gene is located on chromosome 3q26 and its 
inappropriate expression is often caused by 3q abnormalities such as inv(3)(q21q26.2) or 
t(3;3)(q21;q26.2).
6
 According to the World Health Organization classification, AML with 
inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is associated with normal or elevated platelet counts 
and shows increased atypical bone marrow (BM) megakaryocytes and associated 
multilineage dysplasia.
7
 Furthermore, monosomy 7 and 11q23 translocations involving the 
mixed lineage leukemia (MLL) gene are frequently accompanied by deregulated 
expression of EVI1.
2,4,5
 Regardless of cytogenetics, high EVI1 expression predicts adverse 
outcome mainly due to a poor therapeutic response.
2,4,5,8 
In addition to adult AML cases 
described above, elevated expression of EVI1 is frequently observed in pediatric AML 
with MLL rearrangements and monosomy 7.
9
 Importantly, recent reports have suggested 
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that high EVI1 expression can serve as a poor prognostic indicator in pediatric AML 
harboring MLL rearrangements.
10,11
 
Evi1 plays a pivotal role in regulating the self-renewal capacity of hematopoietic 
stem cells (HSCs) during both fetal and adult hematopoiesis. The number of HSCs in the 
para-aortic splanchnopleural region is significantly decreased in Evi1-deficient mice, and 
their long-term repopulation capacity is impaired.
12
 Evi1 deletion also leads to severe 
reduction in fetal liver HSCs along with defective multilineage reconstitution ability.
13
 
Furthermore, conditional knockout (cKO) of Evi1 in adult mice results in significant loss 
of repopulating ability of HSCs.
13
 Together with the finding that Evi1 is predominantly 
expressed in murine HSCs with long-term multilineage repopulating activity,
14
 Evi1 works 
as a key molecule that governs HSC homeostasis. One of the functional features of Evi1 is 
the direct transcriptional regulation of target genes. So far, several essential molecules 
involved in the maintenance of HSCs, including Gata2,
12,15
 Pbx1,
16
 and Pten,
17
 have been 
identified as downstream targets of Evi1. In addition to its DNA-binding capacity, Evi1 
physically interacts with transcription factors to repress hematopoietic differentiation. For 
example, Evi1 inhibits the transcriptional activities of Runx1,
18
 PU.1,
19
 and Gata1
20
 
through direct binding, which results in suppression of granulocyte differentiation, 
myelopoiesis, and erythroid differentiation, respectively. These findings reinforce the 
important role of Evi1 in proper maintenance of HSCs. 
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Meanwhile, Evi1 exerts diverse oncogenic functions such as perturbed cell 
proliferation and anti-apoptotic capacity. For example, Evi1 suppresses the 
growth-inhibitory effects of transforming growth factor- by interacting with SMAD3.21 
Evi1 also directly inhibits c-Jun N-terminal kinase to block stress-induced apoptosis.
22
 
Recent reports have suggested that Evi1 physically interacts with multiple components of 
the epigenetic machinery, including C-terminal binding protein,
23
 histone deacetylases,
24
 
histone methyltransferases,
25
 DNA methyltransferases,
26
 and histone acetyltransferases,
27
 
thus demonstrating a wide variety of roles in gene regulation. Under Evi1-overexpression, 
Evi1 recruits polycomb repressive complexes to the PTEN locus to epigenetically repress 
PTEN transcription, which leads to the activation of AKT/mammalian target of rapamycin 
(mTOR) signaling in Evi1 leukemia cells.
17
 These findings illustrate that deregulation of 
Evi1 expression and/or function in HSCs causes global epigenetic perturbation to induce 
leukemogenesis. In addition, several surface molecules that are specifically expressed in 
Evi1 leukemia cells have been identified. CD52, a lymphocyte marker, is expressed in 
EVI1-high AML cell lines as well as in patients’ samples, and anti-CD52 monoclonal 
antibody (Alemtuzumab) is effective for killing these cells.
28
 Integrin alpha 6 (ITGA6) is 
shown to be expressed in EVI1-high AML cells and confers drug resistance by enhancing 
cell adhesion.
29
 More recently, GPR56, one of the G protein-coupled receptors, is reported 
to be involved in the high cell adhesion and anti-apoptotic property of EVI1-high AML 
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cells.
30
 Taken together, AML with enhanced Evi1 expression can be developed and 
maintained by deregulated transcriptional networks, signaling pathways, and interaction 
with microenvironments, possibly explaining the poor therapeutic responses to 
conventional chemotherapy and the high relapse rates. 
In this study, I sought to clarify novel molecular features of AML with high Evi1 
expression using the mouse model of Evi1 leukemia previously established
17,31 
in 
combination with microarray data analysis. By analyzing gene expression data of AML 
patients, I first revealed that the expression of ITGA2B (CD41), a megakaryocytic 
differentiation marker, positively correlates with that of EVI1. In Evi1 leukemia mice, a 
subpopulation of leukemia cells did express CD41. Importantly, CD41
+
 Evi1 leukemia 
cells had a more efficient leukemia-initiating capacity (LIC) than CD41
−
 cells. In addition, 
Mpl, the receptor for thrombopoietin (THPO), was predominantly expressed in the CD41
+
 
cells, and stimulation by THPO supported their growth and survival via upregulation of 
BCL-xL. These results suggest that the THPO/MPL pathway can be critical for the 
progression of Evi1 leukemia as a cell-extrinsic factor. 
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Methods 
Vectors 
Retroviral vectors used in this study were as follows: pMYs-mouse Evi1-internal ribosome 
entry site (IRES)-green fluorescent protein (GFP),
17
 pMSCV-MLL-ENL-IRES-GFP,
32
 
pMSCV-neo-Flag-MLL-ENL,
32
 and pGCDNsam-MOZ-TIF2-IRES-enhanced GFP.
33
 Evi1 
cDNA was kindly provided by Dr. Kazuhiro Morishita. MLL-ENL cDNA was a gift from 
Dr. Ryoichi Ono and Dr. Tetsuya Nosaka. MOZ-TIF2 cDNA was a gift from Dr. Issay 
Kitabayashi. The pMYs-mouse Evi1-IRES-GFP vector was kindly provided by Dr. Takuro 
Nakamura. Murine Evi1 gene used in this study encodes the Evi1 isoform of Mds1 and 
Evi1 complex locus (Mecom), and its sequence information has been registered with the 
accession number JQ665270.1 in GenBank. 
 
Retroviral transduction 
To produce retroviruses, Plat-E packaging cells (kindly provided by Dr. Toshio 
Kitamura)
34
 were transiently transfected with retroviral constructs using Fugene 6 
transfection reagent (Roche Applied Science, Basel, Switzerland). Viral supernatants were 
harvested after 48 hours and added to the culture plate coated with RetroNectin (Takara 
Bio, Otsu, Japan). Cells were seeded onto the virus-binding plate and infected with 
retroviruses for 48 hours. 
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Myeloid transformation 
Transformation of primary murine BM cells by Evi1 and MLL-ENL was carried out as 
described previously.
32
 Briefly, for establishing Evi1-immortalized cells, c-kit
+
 BM 
mononuclear cells (BM-MNCs) were retrovirally transduced with Evi1-GFP for 48 hours. 
For producing MLL-ENL-immortalized cells, BM-MNCs isolated from mice treated with 
5-fluorouracil (5-FU) were retrovirally transduced with pMSCV-MLL-ENL-IRES-GFP for 
48 hours. GFP-positive cells were sorted and cultured in cytokine-supplemented 
methylcellulose medium (MethoCult GF M3434 from StemCell Technologies, Vancouver, 
BC, Canada). Colonies were replated in M3434 weekly. After 3 or 4 rounds of replating, 
immortalized cells were used for subsequent experiments. 
 
Leukemia mouse models 
Evi1 leukemia mice were established as described previously.
17,31
 In brief, BM-MNCs 
isolated from C57BL/6 mice after treatment with 5-FU were retrovirally transduced with 
Evi1. The infected cells were injected through the tail vein into sublethally irradiated (5.25 
Gy) syngeneic recipient mice. Generation of MLL-ENL and MOZ-TIF2 leukemia mice 
was performed as previously reported.
32,33
 In brief, BM-MNCs harvested from 
5-FU-treated mice were transduced with pMSCV-neo-Flag-MLL-ENL, and transduced 
cells were transplanted into sublethally irradiated mice. For generation of MOZ-TIF2 
9 
 
leukemia mice, lineage
−
/c-kit
+
/Sca-1
−
/FcγRhigh/CD34+ granulocyte-monocyte progenitors 
isolated from C57BL/6 mice were transduced with MOZ-TIF2 and transplanted into 
sublethally irradiated mice. All animal experiments were approved by The University of 
Tokyo Institutional Animal Care and Use Committee. 
 
Flow cytometry 
Cell sorting and analysis were performed by using FACSAriaII, FACSAriaIII, and LSRII 
(all from BD Biosciences, San Jose, CA). The data were analyzed using FACSDiva 
software (BD Biosciences) and FlowJo software (Tree Star, Ashland, OR).  
Fluorochrome-conjugated antibodies used for staining murine cells were as 
follows: phycoerythrin (PE) anti-CD41 (BioLegend, San Diego, CA, USA), 
allophycocyanin (APC) anti-CD41 (eBioscience, San Diego, CA, USA), APC anti-c-kit 
(BioLegend), PECy7 anti-c-kit (BioLegend), PerCP/Cy5.5 anti-c-kit (BioLegend), PE 
anti-Gr-1 (BioLegend), APC anti-Gr-1 (BioLegend), APC anti-Mac-1 (BioLegend), APC 
anti-CD150 (BioLegend), and biotinylated anti-CD150 (BioLegend). The anti-mouse Mpl 
monoclonal antibody (clone AMM2; provided by Kyowa Hakko Kirin) was labeled with 
Alexa Fluor 647 using the Alexa Fluor 647 Monoclonal Antibody Labeling Kit (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. PI (propidium iodide) or 
DAPI (4',6-diamidino-2-phenylindole) was used to exclude dead cells. 
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 For sorting CD41
+
 and CD41
−
 Evi1 leukemia cells, BM- or spleen (SP)-MNCs 
were stained with an APC anti-CD41 antibody. CD41
+
 and CD41
−
 cells within a GFP
+
 
fraction were sorted and subjected to analysis. 
 For sorting subfractions of Evi1 leukemia cells, BM-MNCs were stained with 
PECy7 anti-c-kit, PE anti-CD41, and APC anti-CD150 antibodies. Among c-kit
+
 cells in a 
GFP
+
 fraction, 4 subfractions were defined as follows: Fr.1 (CD41
+
/CD150
+
), Fr.2 
(CD41
+
/CD150
−
), Fr.3 (CD41
−
/CD150
+
), and Fr.4 (CD41
−
/CD150
−
). These fractions were 
sorted and subjected to a transplantation assay. 
 For sorting subfractions of human AML cells, cells were stained with APC 
anti-CD41, PE anti-CD34, and fluorescein isothiocyanate (FITC) anti-CD38 antibodies (all 
from BioLegend). 7-AAD (7-aminoactinomycin D) was used to exclude dead cells. 
CD34
+
/CD41
+
 and CD34
+
/CD41
−
 fractions were sorted and subjected to quantitative 
real-time polymerase chain reaction (qPCR) analysis. For 1 patient’s sample, 
CD34
+
/CD38
−
/CD41
+
, CD34
+
/CD38
−
/CD41
−
, CD34
+
/CD38
+
/CD41
+
, and 
CD34
+
/CD38
+
/CD41
− 
fractions were sorted. 
 
Limiting dilution transplantation assay 
Four subfractions were sorted from secondary Evi1 leukemia BM cells as described above. 
Cells in each fraction were intravenously injected into sublethally irradiated (5.25 Gy) 
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mice and monitored for disease development. Incidence of leukemia in mice was evaluated 
at 20 weeks post-transplantation. 
 
Culture of OP9 cells 
OP9 stromal cells obtained from RIKEN Cell Bank (Tsukuba, Japan) were maintained on a 
gelatin-coated culture dish in -MEM (Wako Pure Chemical Industries, Osaka, Japan) 
supplemented with 20% FCS and 1% penicillin-streptomycin.  
 
In vitro culture of leukemia cells 
For colony-forming cell assays, CD41
+
 and CD41
−
 Evi1 leukemia cells (each 1 × 104) 
were seeded in MethoCult M3434. After 7 days culture, colonies were counted. For cell 
proliferation and apoptosis assays, CD41
+
 and CD41
−
 Evi1 leukemia cells (each 5 × 104 
per well) were seeded onto a confluent layer of OP9 stromal cells in a 24-well plate in the 
presence of stem cell factor (SCF) (50 ng/mL) and/or THPO (50 ng/mL). The anti-mouse 
Mpl antibody was added to the culture to block THPO/MPL signaling. Chemical inhibitors 
used were AG490 (Merck Millipore, Billerica, MA), PD98059 (Cayman Chemical, Ann 
Arbor, MI), Ly294002 (LC Laboratories, Woburn, MA), and WEHI-539-hydrochloride 
(ChemScene, Monmouth Junction, NJ). The half of the culture medium was replaced every 
2 days. After 7 days culture, cells were harvested by trypsinization and the number of 
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viable leukemia cells was determined using trypan blue exclusion. Leukemia cells were 
distinguished from OP9 cells under the microscope by their difference in cell size. For an 
in vitro cytokine stimulation assay, Evi1 or MLL-ENL leukemia cells were serum-starved 
in -MEM containing 1% bovine serum albumin (BSA) at 37°C for 60 minutes. Cells 
were then suspended in -MEM containing 0.1% BSA and stimulated with SCF (50 
ng/mL) or THPO (50 ng/mL) at 37°C for 60 minutes. Unstimulated controls were also 
prepared in parallel. 
 
Cell-cycle analysis 
Cells were fixed with 70% cold ethanol at 4°C for at least 12 hours and stained with 
phosphate-buffered saline (PBS) containing 50 g/mL PI and 250 g/mL RNaseA at 37°C 
for 30 minutes. Cell-cycle distribution was analyzed by fluorescence-activated cell sorter 
(FACS). 
 
Apoptosis analysis 
Cells were harvested and suspended in binding buffer (10 mM Hepes [pH 7.5], 140 mM 
NaCl, and 2.5mM CaCl2) with APC-Annexin V (BD Biosciences). After incubation for 15 
minutes in the dark, cell viability was analyzed by FACS. OP9 cells were gated out using 
forward and side scatter plots. 
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QPCR 
Total RNA was isolated by using RNeasy kit (QIAGEN, Hilden, Germany) or NucleoSpin 
kit (Takara Bio), and the cDNA was synthesized using SuperScript III reverse transcriptase 
(Invitrogen) or ReverTra Ace (Toyobo, Osaka, Japan). QPCR was performed by using 
FastStart SYBR Green Master (Roche Applied Science) or THUNDERBIRD qPCR Mix 
(Toyobo), with a LightCycler 480 System (Roche Applied Science) according to the 
manufacturer’s instructions. The results were normalized to the expression levels of 18S 
rRNA and GAPDH for murine and human cells, respectively. PCR primers used were as 
follows: mEvi1_F, cgaacctaacacggcacttgag; mEvi1_R, ctgcaggttggaagaaatgctg; mItga2b_F, 
cagccactttggcttctcag; mItga2b_R, acggctccagtctcctcttg; MLL-ENL_F, 
gtcagaaacctaccccatcag; MLL-ENL_R, gccgagacattcccttctt; mMpl_F, 
gggcctactgctgctaaagtg; mMpl_R, acccggtgtaggtctggaag; mBcl-xL_F, 
tgaatgaccacctagagccttg; mBcl-xL_R, tcccgtagagatccacaaaagtg; mBcl-2_F, 
gaaccggcatctgcacac; mBcl-2_R, catgctggggccatatagttc; mMcl-1_F, cggccttcctcactcctg; 
mMcl-1_R, tttctccgcaggccaaac; m18SrRNA_F, gactcaacacgggaaacctcac; m18SrRNA_R, 
atcgctccaccaactaagaacg; hEVI1_F, ccaagtttttcctgatttgcaaagc; hEVI1_R, 
cctctcttcagtatgtgacagca; hGAPDH_F, acaccatggggaaggtgaag; hGAPDH_R, 
gtgaccaggcgcccaata. 
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Western blotting 
Cells were lysed with radio-immunoprecipitation assay buffer containing 1 mM sodium 
vanadate, 1 mM PMSF (phenylmethylsulfonyl fluoride), and complete protease inhibitor 
cocktail (Roche Applied Science). The lysates were subjected to SDS-PAGE followed by 
immunoblotting. The primary antibodies used were as follows: anti-STAT3, 
anti-phospho-STAT3 (Tyr705), anti-ERK1/2, anti-phospho-ERK1/2 (Thr202/Tyr204), 
anti-AKT, anti-phospho-AKT (Ser473), anti-BCL-xL, anti-BCL-2, anti-MCL-1, and 
anti--Actin antibodies were from Cell Signaling Technology (Danvers, MA, USA); 
anti-STAT5 and anti-phospho-STAT5 (Tyr694) antibodies were from BD Biosciences. 
HRP-linked anti-rabbit IgG (Cell Signaling Technology) and HRP-linked anti-mouse IgG 
(Santa Cruz Biotechnology, Dallas, TX) were used as secondary antibodies. Proteins were 
detected by ImmunoStar LD (Wako Pure Chemical Industries) with a LAS-4000 system 
(Fujifilm, Tokyo, Japan). Densitometric quantification was performed using ImageJ 
software (http://rsbweb.nih.gov/ij). 
 
Microarray data analysis 
Gene expression data of 461 human individuals with AML were obtained from Gene 
Expression Omnibus (GEO; www.ncbi.nlm.nih.gov/geo, accession number GSE6891).
35 
The raw data of the 460 samples available were processed and normalized using the 
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Microarray Analysis Suite 5.0 algorithm (Affymetrix, Santa Clara, CA). Samples were 
arranged in order of mean expression values of 3 MDS1 and EVI1 complex locus 
(MECOM) probes (probe ID: 215851_at, 221884_at, and 226420_at). Top 30 samples 
were defined as the EVI1-high group according to diagnostic information about EVI1 
positivity attached to each data file. Differentially expressed probe sets between the 
EVI1-high group (30 cases) and the EVI1-low group (430 cases) were determined by fold 
change (FC) > 1.4 and P < .05, and 573 probes highly expressed in the EVI1-high group 
were extracted. These probe IDs were converted into official gene symbols (400 genes) 
using DAVID database (http://david.abcc.ncifcrf.gov). For revealing functional gene 
signatures in the EVI1-high group, gene set enrichment analyses (GSEA) was performed 
with GSEA version 2.0 software available from the Broad Institute 
(http://www.broad.mit.edu/gsea). All curated gene sets (C2) were utilized for analysis. 
Ratio of classes was applied as metric for ranking genes and the data permutations were 
performed 1,000 times. Differences were considered statistically significant at nominal P 
value < .05. 
 For analyzing another set of human AML microarray data, gene expression data 
of 422 AML cases were utilized.
36
 The data normalized were obtained from GEO 
(accession number GSE37642; Platform GPL96). Samples were arranged in order of mean 
expression values of 2 MECOM probes (probe ID: 215851_at and 221884_at), and then 
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divided into the EVI1-high group (n = 42) and the EVI1-low group (n = 380) based on a 
provisional threshold of 90 percentile. Differentially expressed probe sets between 2 
groups were determined by FC > 1.4 and P < .05, and 177 probes highly expressed in the 
EVI1-high group were extracted. These probe IDs were converted into official gene 
symbols (144 genes) using DAVID database. 
 Gene expression data of murine c-kit
+
/Sca-1
+
/lineage
−
 cells (referred to as KSL) 
derived from Evi1 wild-type and cKO mice were analyzed.
13
 The data normalized were 
obtained from the GEO database (accession number GSE11557). Differentially expressed 
probe sets between KSL derived from Evi1 cKO mice (n = 2) and that derived from Evi1 
wild-type mice (n = 2) were determined by FC > 1.4 and P < .05, and 1844 probes 
downregulated by Evi1 deletion were extracted. These probe IDs were converted into 
official gene symbols (2199 genes) using DAVID database. 
 To further identify genes highly associated with Evi1 expression, common genes 
were extracted from 2 gene sets described above: 400 genes highly expressed in the 
EVI1-high AML group (GSE6891) and 2199 genes repressed by Evi1 deletion (GSE11557). 
The list of 42 candidate genes, including 11 cell-surface molecules, is shown in Table 1. 
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Table 1. The list of 42 candidate genes highly correlating with EVI1 expression 
identified by combined analysis of human AML microarray (GSE6891) and Evi1 cKO 
mice microarray (GSE11557) data 
 
Symbol Official gene name Probe ID FC 
ABAT 4-aminobutyrate aminotransferase 224098_at 1.435  
ABCA1* ATP-binding cassette, sub-family A (ABC1), member 1 203504_s_at 1.513  
ARHGAP6 Rho GTPase activating protein 6 206167_s_at 1.470  
ATF7IP activating transcription factor 7 interacting protein 216197_at 1.428  
BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 
1559078_at 1.607  
222891_s_at 1.412  
BCL2 B-cell CLL/lymphoma 2 232614_at 1.539  
BEX2 brain expressed X-linked 2 224367_at 1.877  
CMTM8* CKLF-like MARVEL transmembrane domain containing 8 235099_at 1.618  
COL18A1 collagen, type XVIII, alpha 1 209081_s_at 1.799  
DACH1 dachshund homolog 1 (Drosophila) 
1567101_at 3.060  
228915_at 1.979  
205471_s_at 1.939  
1562342_at 1.915  
205472_s_at 1.717  
EFHC2 EF-hand domain (C-terminal) containing 2 220591_s_at 2.241  
GPR56* G protein-coupled receptor 56 
212070_at 1.839  
206582_s_at 1.679  
HES1 hairy and enhancer of split 1, (Drosophila) 203395_s_at 1.401  
HTR1F* 5-hydroxytryptamine (serotonin) receptor 1F 221458_at 2.119  
ITGA2B*† 
integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, 
antigen CD41) 
206494_s_at 2.573  
216956_s_at 1.812  
206493_at 1.806  
ITGB3*† integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 
204627_s_at 1.970  
204625_s_at 1.438  
ITPR3 inositol 1,4,5-triphosphate receptor, type 3 201189_s_at 1.415  
KRT18 keratin 18 201596_x_at 2.002  
LTBP3 latent transforming growth factor beta binding protein 3 219922_s_at 1.827  
MMRN1 multimerin 1 205612_at 4.701  
MPL*† myeloproliferative leukemia virus oncogene 207550_at 1.404  
MYLK myosin light chain kinase 
224823_at 2.488  
202555_s_at 1.567  
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NFIA nuclear factor I/A 
224970_at 1.801  
224975_at 1.786  
232997_at 1.457  
NRN1* neuritin 1 218625_at 1.867  
NXN nucleoredoxin 219489_s_at 1.465  
OBSL1 obscurin-like 1 212775_at 1.424  
PEAR1*† platelet endothelial aggregation receptor 1 228618_at 1.944  
PELI1 pellino homolog 1 (Drosophila) 
232213_at 1.571  
232304_at 1.529  
PFKM phosphofructokinase, muscle 210976_s_at 1.543  
PTK2 PTK2 protein tyrosine kinase 2 208820_at 1.444  
PTPRD* protein tyrosine phosphatase, receptor type, D 
213362_at 2.679  
214043_at 2.514  
205712_at 1.685  
RAB27B RAB27B, member RAS oncogene family 207018_s_at 1.428  
RBM38 RNA binding motif protein 38 212430_at 1.409  
RBMS3 RNA binding motif, single stranded interacting protein 238447_at 1.422  
RFTN1 raftlin, lipid raft linker 1 242672_at 1.426  
RUNX3 runt-related transcription factor 3 
204198_s_at 1.465  
204197_s_at 1.455  
SELP*† selectin P (granule membrane protein 140kDa, antigen CD62) 206049_at 1.495  
SMAD3 SMAD family member 3 239448_at 1.511  
SOCS2 suppressor of cytokine signaling 2 
203372_s_at 2.411  
203373_at 2.316  
SPOCK2 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 2 
202524_s_at 1.425  
SSBP2 single-stranded DNA binding protein 2 
1557813_at 1.587  
1561690_at 1.505  
1557814_a_at 1.433  
ZBTB46 zinc finger and BTB domain containing 46 227329_at 1.735  
 
FCs calculated from the microarray data of human AML samples are shown. 
* These genes represent cell-surface marker genes. 
† These genes represent surface markers of megakaryocyte and platelet lineage. 
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Short hairpin RNA-mediated knockdown of Mpl 
A target sequence for Mpl short hairpin RNA (shRNA) was identified by using Clontech 
RNAi Target Sequence Selector. The oligonucleotides encoding Mpl shRNA and control 
shRNA were cloned into the pSIREN-RetroQ retroviral vector (Takara Bio) according to 
the manufacturer’s instructions. BM cells derived from Evi1 leukemia mice were 
precultured in -MEM supplemented with 20% FCS, 1% penicillin-streptomycin and 
cytokines (40 ng/mL SCF, 10 ng/mL IL-3, 20 ng/mL IL-6, 20 ng/mL THPO, and 20 ng/mL 
Flt3 ligand) and subjected to retroviral infection as described above. After 48 hours of 
culture, cells were collected and further cultured in fresh medium containing 1.5 g/mL 
puromycin for 72 hours. Puromycin-resistant cells were used for BM transplantation 
assays. The target sequences were as follows: Mpl, CAGTGACAATTGGACTTCA; 
control, AAATGTACTGCGTGGAGAC. 
 
Human samples 
A total of 4 BM cells derived from patients with AML were obtained from the Department 
of Hematology and Oncology of The University of Tokyo Hospital. The study was 
approved by the ethics committee of The University of Tokyo, and written informed 
consent in accordance with the Declaration of Helsinki was obtained from all patients 
whose samples were collected. 
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Statistics 
The data were analyzed by Student t test, Tukey’s test, or Dunnett’s test. Differences were 
considered statistically significant at P < .05. To analyze the survival curve, the log-rank 
test was used. LIC frequency was calculated by Poisson statistics. Data analysis was 
performed using R software (http://www.R-project.org). 
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Results 
Expression of ITGA2B correlates with that of EVI1 in human AML 
First, I analyzed 2 sets of microarray data and identified 42 genes that were highly 
associated with EVI1 expression, including 11 cell-surface molecules (Figure 1A and Table 
1). The reason for focusing on cell-surface molecules is that these surface markers enable 
the separation of cell populations and comparison of their leukemic properties in both Evi1 
leukemia mice and in human AML subjects. These candidate cell-surface molecules 
included several megakaryocyte/platelet lineage markers such as ITGA2B (CD41), ITGB3 
(CD61), PEAR1, SELP, and MPL. Analysis of another set of AML microarray data
36
 
confirmed that the expression of ITGA2B, MPL, and SELP was correlated with that of 
EVI1 (Table 2). In addition, GSEA revealed that molecular signatures relevant to platelet 
function and integrin IIb3 (CD41/CD61) signaling were significantly enriched in the 
EVI1-high group (Figure 1B–E). These results indicate that the expression of 
megakaryocytic markers, in particular ITGA2B, strongly correlates with that of EVI1 in 
human AML. 
Expression levels of candidate megakaryocytic marker genes were comparable 
between EVI1-high cases with 3q abnormalities and those without 3q abnormalities 
(Figure 2A). When compared with MLL-rearranged cases without EVI1 expression, those 
with EVI1 overexpression showed higher expression of ITGA2B, MPL, and PEAR1 (Figure 
22 
 
2B). These results suggested that expression of megakaryocytic marker genes would mark 
EVI1-positive AML cases irrespective of cytogenetic abnormalities. 
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Figure 1. Genes expressed in the megakaryocyte and platelet lineage correlate with 
EVI1 expression. 
(A) The candidate genes positively correlated with EVI1 expression were extracted by 
analyzing 2 different sets of microarray data: (i) human AML BM specimens (GSE6891) 
and (ii) KSL cells derived from Evi1 cKO mice (GSE11557). For human AML microarray 
analysis, samples were divided into EVI1-high AML (30 cases) and EVI1-low AML (430 
cases) groups according to EVI1 expression as well as diagnostic information, and then 
400 genes highly expressed in the EVI1-high AML group were identified (FC > 1.4 and P 
< .05). From Evi1 cKO mice microarray data, 2199 genes downregulated by 
Evi1-knockout in KSL cells were extracted (FC > 1.4 and P < .05). The Venn diagram 
revealed that 42 genes were highly correlated with EVI1 expression. (B–E) According to 
the GSEA, several gene sets related to platelet function were enriched in the EVI1-high 
AML group compared with the EVI1-low AML group. (B) Gene set name, 
REACTOME_FORMATION_OF_PLATELET_PLUG; 174 genes. (C) Gene set name, 
REACTOME_INTEGRIN_ALPHAIIBBETA3_SIGNALING; 23 genes. (D) Gene set 
name, REACTOME_PLATELET_ACTIVATION; 155 genes. (E) Gene set name, 
REACTOME_HEMOSTASIS; 262 genes. NES indicates the normalized enrichment score.  
A
(i) Human AML microarray
genes highly expressed in 
EVI1-high cases
P < 0.05
Fold change > 1.4
(ii) Evi1 cKO mice microarray
genes repressed by 
Evi1-knockout in KSL
P < 0.05
Fold change > 1.4
400 genes 2199 genes
42
genes
D E
B C
NES = 1.92
Nominal P = 0.025
NES = 1.86
Nominal P = 0.025
NES = 1.78
Nominal P = 0.044
NES = 1.69
Nominal P = 0.047
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Table 2. The list of 144 genes highly correlating with EVI1 expression in another set 
of human AML microarray data (GSE37642) 
 
ABCA1 ABLIM1 ACOX2 ALDH1A1 ANGPT1 ARHGAP6 ARMCX1 ASAP2 
C1orf54 CD1D CD300A CD48 CD52 CD7 CHRDL1 CLEC2B 
CNN3 COL5A1 CRABP1 CRIM1 CSF1 DACH1 DBNDD2 DCHS1 
DSG2 DUSP7 DZIP1 EFHC2 EGR3 EPS8 ERG ETV5 
FAM30A FCER1A FEZ1 FHL2 FRMD4B FZD6 FZD7 GALNT12 
GJA1 GNAI1 GP1BB GPR126 GPR56 GPRC5C GUCY1B3 H2AFY 
HOPX HOXA10 HOXA11 HPGD HTR1F ID4 IGHG1 IL12RB2 
IL7 INHBA INPP4B IPW ITGA2B ITGA6 KDELC1 KIAA0125 
KRT18P19 LAG3 LGALS1 LMO4 LOC100134230 LOC731884 LOX LRBA 
LST1 LTBP3 MAF MECOM MEF2C MEIS1 MFAP3L MICAL1 
MLLT3 MMRN1 MN1 MPL MPPED2 MS4A2 MYL9 MYO6 
NAP1L3 NGFRAP1 NPDC1 NRIP1 NRXN2 NYNRIN OBSL1 PAWR 
PCDH9 PDLIM2 PDLIM5 PLCB4 PLEKHA5 PLS3 PRDX1 PRKACB 
PRKCH PRKCZ PRKD3 PRR16 RBM47 RBP4 RBPMS SCD 
SDPR SELP SENP6 SERPINE2 SERPING1 SH3BP4 SH3BP5 SMAD7 
SNRPN SOCS2 SPAG6 SPP1 TCF7L2 TIE1 TIMP3 TKTL1 
TNFSF10 TNNT1 TOX TPBG TPM2 TRPM4 TRPS1 TSPAN4 
VWA5A VWF WBP5 WHAMML1 XAF1 XAGE1B ZEB1 ZNF232 
 
Genes colored in gray are commonly found in Table 1. 
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Figure 2. Comparison of expression levels of megakaryocytic surface marker genes 
by human AML microarray data analysis. 
(A) Comparison of gene expression levels between EVI1-high cases with 3q abnormalities 
(n = 5) and those without 3q abnormalities (n = 25) (GSE6891). The expression levels of 
ITGA2B, ITGB3, PEAR1, SELP, and MPL were comparable irrespective of the presence of 
3q abnormalities (NS means not significant; Student t test). All probe IDs examined are 
described in Table 1. 
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Figure 2. Comparison of expression levels of megakaryocytic surface marker genes 
by human AML microarray data analysis. (continued) 
(B) Comparison of gene expression levels between EVI1-positive MLL-rearranged cases (n 
= 3) and EVI1-negative MLL-rearranged cases (n = 7) (GSE6891). Among genes examined, 
the expression levels of ITGA2B, PEAR1, and MPL in EVI1-positive MLL-rearranged 
cases were higher than those in EVI1-negative MLL-rearranged cases (*P < .05, ***P 
< .001, Student t test). 
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Evi1-overexpressing cells express CD41 
To confirm the association between CD41 and Evi1, I next examined CD41 expression in 
hematopoietic cells immortalized by Evi1. Murine c-kit
+
 BM cells were transduced with 
Evi1-GFP or mock-GFP retroviral vectors, and GFP
+
 cells were sorted and subjected to 
qPCR and FACS analysis (Figure 3A). Itga2b expression was increased 1.5-fold by Evi1 
overexpression 2 days after transduction (Figure 3B). After 3 rounds of replating in 
semisolid culture, transformed Evi1-GFP
+
 cells clearly expressed CD41 (Figure 3C). To 
exclude the possibility that immortalized CD41
+
 cells are generated exclusively from the 
CD41
+
 normal BM cells transduced with Evi1, CD41
−
 BM cells were purified and 
transduced with Evi1 (Figure 4A). Even in this setting, Evi1 overexpression induced 
CD41
+
 immortalized cells (Figure 4B). I next examined CD41 expression in 
MLL-ENL-transduced murine BM cells in which Evi1 expression can be upregulated.
32
 
BM cells from 5-FU-treated mice were transduced with MLL-ENL and immortalized in a 
semisolid culture. In this way, I obtained 2 Evi1-positive and 2 Evi1-negative clones 
(Figure 5A). The expression levels of the MLL-ENL transgene were comparable among 
these clones, except in 1 Evi1-positive clone in which MLL-ENL expression was 
approximately 2 times higher than that of the others. As described in a previous report, 
efficient Evi1-upregulation is observed when immature KSL cells rather than BM 
progenitor cells are transduced with MLL-ENL.
32
 The fact that Evi1-positivity differed 
28 
 
among 4 clones might reflect a difference in 5-FU-primed BM cell populations 
transformed by MLL-ENL in each experiment. Although upregulation of Evi1 was 
relatively mild compared with the forced expression, the Evi1
+
 clones clearly showed 
higher expression of Itga2b than the Evi1
−
 clones and expressed CD41 (Figure 5B–C). 
These results demonstrate that CD41 expression is accompanied by Evi1 expression in 
mouse BM cells immortalized in vitro.  
 
 
29 
 
 
 
Figure 3. Evi1-overexpressing cells express CD41. 
(A) Schematic representation of gene expression and FACS analysis. Murine c-kit
+
 BM 
cells were transduced with Evi1-GFP or mock-GFP for 2 days, and GFP
+
 cells were sorted 
and subjected to gene expression analysis. Evi1-GFP-transduced cells were seeded in 
cytokine-supplemented methylcellulose culture medium (MethoCult M3434) and serially 
replated. FACS analysis was performed at the third replating. Three independent 
experiments were performed. (B) The messenger RNA (mRNA) expression of Evi1 (left) 
and Itga2b (right) was compared between Evi1-GFP- and mock-GFP-transduced murine 
BM cells. Expression levels relative to normal c-kit
+
 BM cells are presented. Error bars 
indicate standard deviation (SD; n = 3; *P < .05, Student t test). (C) Surface CD41 
expression was analyzed by FACS. Cells were stained with a PE-conjugated isotype 
control antibody or a PE-conjugated anti-CD41 antibody. Representative FACS data and a 
bar graph showing frequencies of CD41
+
 cells are presented. Error bars indicate SD (n = 3; 
***P < .001, Student t test). 
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Figure 4. CD41
+
 immortalized cells are generated from CD41
−
 normal BM cells 
transduced with Evi1. 
(A) Murine c-kit
+
 BM-MNCs contained a small fraction of CD41
+
 cells (pre-sort). The 
CD41
+
 cells were completely depleted by cell sorting (post-sort). (B) Purified CD41
−
 cells 
were retrovirally transduced with Evi1-GFP for 2 days. GFP
+
 cells were isolated by FACS 
and seeded onto MethoCult M3434. The surface expression of CD41 was analyzed by 
FACS at the third replating. Representative FACS data and a bar graph showing 
frequencies of CD41
+
 cells are presented. Error bars indicate SD (n = 3; *P < .05, Student t 
test). 
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Figure 5. Evi1
+
 MLL-ENL-immortalized cells express CD41. 
(A) BM-MNCs isolated from 5-FU-treated mice were retrovirally transduced with 
MLL-ENL and immortalized by serially replating in semisolid culture. Four 
MLL-ENL-immortalized clones from 2 independent experiments were established. The 
mRNA expression levels of Evi1 (x-axis) and MLL-ENL (y-axis) are shown. Obviously, 4 
MLL-ENL-transduced clones (closed circles) are divided into Evi1
+
 (n = 2) and Evi1
−
 (n = 
2) clones as indicated. A closed triangle indicates normal c-kit
+
 BM cells. (B) Comparison 
of Itga2b expression levels between Evi1
+
 and Evi1
−
 clones. Expression levels relative to 
normal c-kit
+
 BM cells are presented. Error bars indicate SD. (C) Surface CD41 expression 
was analyzed by FACS. Evi1
+
 clones, but not Evi1
−
 clones, clearly expressed CD41.  
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CD41
+
 Evi1 leukemia cells have a higher LIC than CD41
− 
cells 
Next, I checked CD41 expression in the mouse model of Evi1 leukemia.
17,31
 As shown in 
Figure 6A, CD41 was distinctly expressed in BM and SP cells of Evi1 leukemia mice. 
CD41
+
 cells expressed immature markers such as c-kit and CD150 more frequently than 
CD41
−
 cells (Figure 6B). In contrast, Gr-1- and Mac-1-positive mature cells were 
frequently present in the CD41
−
 fraction. I then postulated that CD41
+
 cells mark a 
phenotypically and functionally immature fraction of Evi1 leukemia mice and contain 
subfraction(s) with a higher LIC. Both CD41
+
 and CD41
−
 cells within a GFP
+
, namely, 
Evi1
+
 fraction were sorted and subjected to further analysis (Figure 7A). Morphological 
analysis revealed that CD41
+
 cells contained myeloblasts with high nucleus/cytoplasm 
ratio more abundantly than CD41
−
 cells (Figure 7B). In a colony-forming assay, CD41
+
 
cells generated larger colonies and showed higher colony-forming capacity than CD41
−
 
cells (Figure 8A). There was no significant difference between CD41
+
 and CD41
−
 cells in 
the cell-cycle status (Figure 8B). On the other hand, apoptotic rates were significantly 
lower in CD41
+
 cells than in CD41
−
 cells (Figure 8C). Next, I performed secondary BM 
transplantation assays, wherein mice received CD41
+
 or CD41
−
 cells developed AML 
characterized by the emergence of large numbers of myeloblasts as observed in primary 
leukemia mice (Figure 6–7) along with marked splenomegaly (data not shown). 
Importantly, the mice transplanted with CD41
+
 cells died from AML more rapidly than 
33 
 
those transplanted with CD41
−
 cells (Figure 9). Expression profiles of CD41 in secondary 
leukemia mice were similar to those in primary leukemia mice (data not shown). Given 
that the significant difference of homing capacity between CD41
+
 and CD41
−
 cells was not 
observed 12 hours after transplantation, delayed onset of AML in mice transplanted with 
CD41
−
 cells might not due to its impaired homing capacity (Figure 10). To further define 
subpopulation(s) with a high LIC, 4 subfractions were classified based on CD41 and 
CD150 expression patterns within GFP
+
/c-kit
+
 cells and transplanted into mice (Figure 
11A). A limiting dilution transplantation assay revealed that 3 fractions other than the 
c-kit
+
/CD41
−
/CD150
−
 fraction (Fr.4) showed extremely high LIC frequencies (Figure 11B). 
These results demonstrated that c-kit
+
/CD41
−
/CD150
+
 (Fr.3) as well as c-kit
+
/CD41
+
 (Fr.1 
and Fr.2) cells marked a LIC within Evi1 leukemia cells. 
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Figure 6. CD41 is expressed in BM and SP cells derived from Evi1 leukemia mice. 
(A) The surface expression of CD41 on Evi1 leukemia cells. BM- and SP-MNCs were 
harvested from Evi1 leukemia mice, and stained with an APC-conjugated anti-CD41 
antibody. Representative FACS data are shown. The graph shows frequencies of CD41
+
 
cells in BM and SP derived from 9 individual leukemia mice. (B) Surface-marker profiles 
of Evi1 leukemia BM cells. Cells were stained with a PE-conjugated anti-CD41 antibody 
and APC-conjugated antibodies (c-kit, CD150, Gr-1, or Mac-1). Data for GFP
+
 cells are 
shown. Bar graphs show frequencies of c-kit
+
, CD150
+
, Gr-1
+
, and Mac-1
+
 cells in CD41
+
 
and CD41
−
 fractions. Error bars indicate SD (n = 5; **P < .01, Student t test). 
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Figure 7. CD41
+
 Evi1 leukemia cells are morphologically more immature cells than 
CD41
−
 cells. 
(A) CD41
+
 and CD41
−
 Evi1 leukemia cells within a GFP
+
 fraction were sorted and 
subjected to further analysis. A representative FACS plot is shown. (B) The morphological 
feature of CD41
+
 and CD41
−
 cells was examined by Wright-Giemsa staining, and the 
proportion of myeloblasts with a high nucleus/cytoplasm ratio was compared between 
these fractions. Pictures were captured by a BH-2 microscope equipped with an NC SPlan 
objective lens and a DP20 camera module (both from Olympus, Tokyo, Japan). Scale bars 
represent 10 m. Error bars indicate SD (n = 5; **P < .01, Student t test). 
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Figure 8. CD41
+
 Evi1 leukemia cells show higher colony-forming capacity and a 
lower apoptotic rate than CD41
−
 cells. 
(A) CD41
+
 and CD41
−
 cells were cultured in MethoCult M3434 medium and examined 
their colony-forming activities. Representative pictures of colonies and a bar graph 
showing colony numbers from each fraction are presented. Scale bars represent 500 m. 
Error bars indicate SD (n = 8; **P < .01, Student t test). (B) The cell-cycle status of CD41
+
 
and CD41
−
 cells was analyzed by PI staining. Error bars indicate SD (n = 3). (C) Apoptosis 
analysis of CD41
+
 and CD41
−
 cells. Freshly isolated BM-MNCs were stained with a 
PE-conjugated anti-CD41 antibody, followed by staining with APC-conjugated Annexin V. 
Apoptotic rates in CD41
+
 and CD41
−
 fractions were determined by FACS. Error bars 
indicate SD (n = 4; *P < .05, Student t test). 
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Figure 9. CD41
+
 Evi1 leukemia cells have a higher LIC than CD41
− 
cells. 
CD41
+
 and CD41
−
 fractions were sorted from primary Evi1 leukemia BM cells and 
intravenously injected into sublethally irradiated (5.25 Gy) mice (1 × 104 cells per mouse). 
Survival curves of mice transplanted with CD41
+
 (n = 9; red line) or CD41
−
 (n = 10; blue 
line) Evi1 leukemia cells are shown (P = .0016, log-rank test). 
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Figure 10. Comparison of homing capacity between CD41
+
 and CD41
− 
Evi1 leukemia 
cells. 
CD41
+
 or CD41
−
 cells sorted from secondary Evi1 leukemia BM cells were transplanted 
into sublethally irradiated mice (4.5 × 105 cells per mouse; n = 4 each). BM- and 
SP-MNCs were harvested 12 hours after transplantation, and frequencies of GFP
+
 cells in 
BM (left) and SP (right) were analyzed by FACS. The significant difference of homing 
capacity between these fractions was not observed (Student t test). 
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Figure 11. Comparison of LIC frequencies in the 4 subfractions of Evi1 leukemia 
cells. 
(A) The GFP
+
/c-kit
+
 fraction in Evi1 leukemia BM cells was divided into 4 subfractions: 
Fr.1 (CD41
+
/CD150
+
), Fr.2 (CD41
+
/CD150
−
), Fr.3 (CD41
−
/CD150
+
), and Fr.4 
(CD41
−
/CD150
−
). (B) LIC frequencies in each fraction as determined by a limiting 
dilution transplantation assay are shown. See Table 3 for detailed transplantation results. 
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Table 3. Limiting dilution transplantation assay data 
 
Cell population Transplanted cells Incidence of leukemia (%) 
Fr.1 
50000 3/3 (100) 
5000 3/3 (100) 
500 1/3 (33) 
Fr.2 
50000 3/3 (100) 
5000 3/3 (100) 
500 2/3 (66) 
Fr.3 
50000 3/3 (100) 
5000 3/3 (100) 
500 2/3 (66) 
Fr.4 
50000 2/3 (66) 
5000 1/3 (33) 
500 0/3 (0) 
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Mpl is predominantly expressed in CD41
+
 Evi1 leukemia cells 
As shown in Table 1 and 2, expression of several megakaryocytic markers correlated with 
that of EVI1. Because Mpl, the THPO receptor, is known as a well-defined molecule, I 
next tested whether Evi1 leukemia cells express Mpl. As shown in Figure 12A, CD41
+
 
cells showed significantly higher Mpl expression than CD41
−
 cells. FACS analysis 
confirmed that Mpl was mainly expressed in the CD41
+
 BM and SP cells (Figure 12B–C). 
I also assessed Mpl expression in other mouse models of myeloid leukemia induced by 
MLL-ENL and MOZ-TIF2 oncogenes. Our previous study showed that Evi1 expression in 
MLL-ENL leukemia mice varied among individuals,
32
 and MLL-ENL leukemia cells used 
here expressed low levels of Evi1 (Figure 13A). Evi1 expression was not detected in 
MOZ-TIF2 leukemia cells. These leukemia cells expressed neither Mpl nor CD41 (Figure 
13B–C). 
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Figure 12. Mpl is predominantly expressed in CD41
+
 Evi1 leukemia cells. 
(A) Mpl expression was measured by qPCR in CD41
+
 and CD41
−
 BM cells of Evi1 
leukemia mice. BM-MNCs were harvested from 5 independent mice and CD41
+
 and 
CD41
−
 cells were sorted. Expression levels relative to normal c-kit
+
 BM cells are presented. 
Error bars indicate SD (*P < .05, Student t test). (B–C) FACS analysis of CD41 and Mpl 
expression in BM- and SP-MNCs from Evi1 leukemia mice. (B) Cells were stained with 
PE-conjugated anti-CD41 and Alexa Fluor 647-labeled anti-mouse Mpl antibodies. 
Expression profiles were analyzed for GFP
+
 cells. (C) Mean fluorescence intensity (MFI) 
of Mpl was quantified in CD41
+
 and CD41
−
 cells. Error bars indicate SD (n = 8; ***P 
< .001, Student t test). 
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Figure 13. Expression of CD41 and Mpl is not induced in other mouse models of 
myeloid leukemia. 
(A) The expression levels of Evi1 (left), Itga2b (middle), and Mpl (right) were measured 
by qPCR for murine leukemia BM cells induced by Evi1, MLL-ENL, or MOZ-TIF2. 
Expression levels relative to normal c-kit
+
 BM cells are presented. Error bars indicate SD 
(Evi1, n = 4; MLL-ENL, n = 3; MOZ-TIF2, n = 2; ND means not detected; **P < .01, 
Student t test). (B) SP-MNCs from MLL-ENL leukemia mice and BM-MNCs from 
MOZ-TIF2 leukemia mice were stained with an APC-conjugated isotype control antibody 
(upper panel) or an APC-conjugated anti-CD41 antibody (lower panel), and analyzed by 
FACS. Representative FACS data are shown. (C) SP-MNCs from MLL-ENL leukemia 
mice and BM-MNCs from MOZ-TIF2 leukemia mice were stained with an Alexa Fluor 
647-labeled anti-mouse Mpl antibody. Representative FACS data are shown (solid line, 
anti-Mpl antibody; filled histogram, isotype control). 
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THPO/MPL signaling enhances the growth and survival of CD41
+
 Evi1 leukemia cells 
In the hematopoietic system, THPO plays an important role not only in regulating 
megakaryocytic development and platelet production but also in maintaining quiescent 
HSCs in the osteoblastic niche.
37,38
 Therefore, I next examined effects of THPO on CD41
+
 
and CD41
−
 Evi1 leukemia cells cultured on OP9 stromal cells. THPO but not SCF more 
efficiently stimulated the proliferation of CD41
+
 cells than CD41
−
 cells (Figure 14A), 
which correlated well with the expression pattern of Mpl in these fractions. Moreover, the 
combination of THPO and SCF did not show any synergistic effect on cell growth, 
indicating that THPO is sufficient for the growth of CD41
+
 cells. Because CD41
+
 and 
CD41
−
 cells produced each other to some extent during the culture on OP9 cells (data not 
shown), the clear effect of THPO on CD41
+
 cells might be masked by the gradual 
appearance of CD41
−
 cells. An anti-Mpl neutralizing antibody, AMM2,
38
 distinctly 
inhibited the THPO-mediated growth of CD41
+
 cells but not CD41
−
 cells (Figure 14B–C). 
In addition, CD41
+
 cells showed a significantly lower apoptotic rate than CD41
−
 cells in 
the presence of THPO (Figure 14D). When CD41
+
 cells were cultured on OP9 feeder cells 
with or without THPO for 3 days, expression of Gr-1 and Mac-1 was not induced even in 
the absence of THPO (Figure 15), indicating that THPO might not inhibit differentiation of 
Evi1 leukemia cells. These results demonstrate that THPO/MPL signaling supports the 
proliferation and suppresses the apoptosis of the CD41
+
 Evi1 leukemia cells.  
45 
 
Upon THPO binding, MPL activates several intracellular signals including Janus 
kinase (JAK)/signal transducer and activator of transcription (STAT), mitogen-activated 
protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK), and 
phosphatidylinositol 3-kinase (PI3K)/AKT pathways. As shown in Figure 16A, STAT3, 
STAT5, and ERK1/2 were markedly phosphorylated in Evi1 leukemia cells stimulated 
with THPO but not SCF. In contrast, remarkable phosphorylation of AKT was not induced. 
Neither THPO nor SCF induced phosphorylation of these molecules in MLL-ENL 
leukemia cells that did not express Mpl (Figure 16B). When CD41
+
 cells were treated with 
a JAK2 inhibitor (AG490) or an MEK inhibitor (PD98059), the number of viable cells 
decreased by approximately 50% compared with those treated with a vehicle control 
(Figure 17A). Furthermore, apoptotic cells increased more than 2-fold by addition of 
AG490 or PD98059 (Figure 17B). Similarly, a PI3K inhibitor, Ly294002, seemed to 
suppress the growth and induce apoptosis of CD41
+
 cells (Figure 18), indicating that the 
PI3K/AKT pathway was actually activated in CD41
+
 cells. These results demonstrate that 
JAK/STAT and MEK/ERK pathways are responsible for the growth-accelerating and 
anti-apoptotic effects of THPO on CD41
+
 Evi1 leukemia cells. 
To test whether THPO/MPL signaling is important for the progression of Evi1 
leukemia in vivo, I constructed a shRNA-expressing retroviral vector targeting Mpl, by 
which Mpl
+
 Evi1 leukemia cells decreased by about 50% (Figure 19A). Survival analysis 
46 
 
revealed that shRNA-mediated knockdown of Mpl in Evi1 leukemia BM cells partially, 
but significantly, prolonged the survival of Evi1 leukemia mice (Figure 19B). 
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Figure 14. THPO/MPL signaling enhances the growth and survival of CD41
+
 Evi1 
leukemia cells. 
(A) Proliferation assays of CD41
+
 and CD41
−
 BM cells from Evi1 leukemia mice using 
OP9 coculture system. CD41
+
 or CD41
−
 cells (5 × 104 cells per well) were seeded onto a 
confluent layer of OP9 stromal cells in the presence of SCF and THPO, THPO alone, or 
SCF alone. After 7 days of culture, cells were harvested by trypsinization and the number 
of viable leukemia cells was counted. Error bars indicate SD (n = 7; **P < .01, ***P 
< .001, Tukey’s test). (B–C) The antiproliferation effect of an anti-Mpl antibody against 
CD41
+
 cells. CD41
+
 (B; n = 4) or CD41
−
 (C; n = 3) cells were seeded onto OP9 stromal 
cells with or without THPO, or THPO with an anti-Mpl antibody (100 ng/mL) and 
cultured for 7 days. The number of viable cells was determined as described in panel A. 
Error bars indicate SD (*P < .05, Dunnett’s test). (D) Apoptosis analysis of CD41+ and 
CD41
−
 cells cocultured with OP9 cells. CD41
+
 or CD41
−
 cells were cultured in the same 
condition as panel A. After 7 days culture, cells were harvested and stained with Annexin V, 
followed by FACS analysis. Error bars indicate SD (n = 3; **P < .01, Tukey’s test). 
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Figure 15. THPO does not inhibit differentiation of CD41
+
 Evi1 leukemia cells 
cultured on OP9 stromal cells. 
CD41
+
 Evi1 leukemia BM or SP cells were cultured on OP9 stromal cells with or without 
THPO for 3 days, and then expression patterns of Mac-1 (A) and Gr-1 (B) were analyzed 
by FACS. Representative FACS plots are shown. Graphs show the frequencies of Mac-1
+
 
or Gr-1
+
 cells in each condition. The significant difference in frequencies was not observed 
(n = 3; Student t test). 
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Figure 16. THPO induces phosphorylation of STAT3, STAT5, and ERK1/2 in Evi1 
leukemia cells. 
(A) BM- and SP-MNCs of Evi1 leukemia mice were serum-starved in -MEM containing 
1% BSA for 60 minutes and then stimulated with SCF or THPO in -MEM containing 
0.1% BSA for 60 minutes. Unstimulated cells were used as negative controls. The 
phosphorylation levels of STAT3, STAT5, ERK1/2, and AKT were analyzed by western 
blotting. (B) SP-MNCs were harvested from 2 independent MLL-ENL leukemia mice in 
which Mpl expression was not observed (shown in Figure 13). The phosphorylation levels 
of STAT3, STAT5, ERK1/2, and AKT were analyzed as described above. 
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Figure 17. Pharmacologic inhibition of JAK/STAT and MEK/ERK pathways 
suppresses proliferation and induces apoptosis of CD41
+
 Evi1 leukemia cells cultured 
on OP9 stromal cells. 
CD41
+
 cells were treated with dimethylsulfoxide (DMSO) as a vehicle control, a JAK2 
inhibitor (AG490; 20 M), or an MEK inhibitor (PD98059; 20 M) on OP9 stromal cells 
in the presence of THPO for 7 days. (A) The number of viable cells was counted. Error 
bars indicate SD (n = 3; Dunnett’s test). (B) The rate of apoptotic cells was determined by 
FACS. Error bars indicate SD (n = 4; *P < .05, Dunnett’s test). 
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Figure 18. Pharmacologic inhibition of the PI3K/AKT pathway suppresses 
proliferation and induces apoptosis of CD41
+
 Evi1 leukemia cells cultured on OP9 
stromal cells. 
CD41
+
 cells were treated with DMSO as a vehicle control and a PI3K inhibitor 
(Ly294002; 5 M) on OP9 stromal cells in the presence of THPO for 7 days. (A) The 
number of viable cells was counted. (B) The rate of apoptotic cells was determined by 
FACS. Error bars indicate SD in each graph (n = 3; Student t test). 
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Figure 19. Knockdown of Mpl by shRNA transduction partially, but significantly, 
prolongs the survival of Evi1 leukemia mice. 
(A) Evi1 leukemia BM cells were retrovirally transduced with Mpl shRNA or control 
shRNA. Transduced cells were then cultured on OP9 stromal cells in the presence of 
THPO. Cells were harvested and stained with an Alexa Fluor 647-labeled anti-mouse Mpl 
antibody. Evi1 leukemia cells expressing Mpl shRNA showed about 50% reduction of 
Mpl
+
 cells compared with those expressing control shRNA. (B) Evi1 leukemia BM cells 
transduced with Mpl shRNA or control shRNA were transplanted into sublethally 
irradiated mice. The survival curves of mice transplanted with Mpl shRNA (n = 6; solid 
line) or control shRNA (n = 6; dotted line) are shown (P = .018, log-rank test). 
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BCL-xL upregulation via THPO/MPL signaling supports CD41
+
 Evi1 leukemia cells 
Because THPO/MPL signaling enhanced the anti-apoptotic property of CD41
+
 Evi1 
leukemia cells, I examined the expression patterns of several anti-apoptotic Bcl-2 family 
genes. Additionally, the finding that BCL-2 was one of the candidate genes highly 
correlated with EVI1 expression (Table 1) led me to explore the functional significance of 
Bcl-2 family genes in Evi1-related leukemogenesis. CD41
+
 cells showed higher expression 
of Bcl-xL and Bcl-2 than CD41
−
 cells (Figure 20A). In contrast, Mcl-1 expression levels 
were comparable between these fractions. Furthermore, BCL-xL was more highly 
expressed in CD41
+
 cells at the protein level than in CD41
−
 cells (Figure 20B). However, 
the expression of BCL-2 and MCL-1 was comparable in these fractions (Figure 20C–D). 
After serum starvation and subsequent stimulation with THPO, the expression of BCL-xL, 
but not BCL-2 and MCL-1, was upregulated in Evi1 leukemia cells (Figure 21). Thus, I 
assumed that BCL-xL is important for the growth and survival of Mpl
+
 Evi1 leukemia cells. 
I examined whether WEHI-539, a highly specific BCL-xL inhibitor,
39
 exerts an inhibitory 
effect on Evi1 leukemia cells cultured on OP9 feeder cells. WEHI-539 seemed to inhibit 
the growth and induce apoptosis of CD41
+
 cells in a dose-dependent manner (Figure 22). 
On the contrary, the growth of CD41
−
 cells was not affected by WEHI-539. These results 
indicate that THPO/MPL signaling supports the growth and survival of Evi1 leukemia 
cells via upregulating BCL-xL. 
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Figure 20. CD41
+
 Evi1 leukemia cells show higher expression of BCL-xL than CD41
−
 
cells. 
(A) Comparison of Bcl-xL (left), Bcl-2 (middle), and Mcl-1 (right) mRNA expression 
between CD41
+
 and CD41
−
 BM cells of Evi1 leukemia mice. CD41
+
 and CD41
−
 BM cells 
were sorted from 5 independent mice. Expression levels relative to normal c-kit
+
 BM cells 
are presented. Error bars indicate SD (*P < .05, Student t test). (B–D) Comparison of 
protein expression of BCL-xL (B), BCL-2 (C), and MCL-1 (D) between CD41
+
 and 
CD41
−
 fractions by western blotting. Representative images and bar graphs showing 
quantified protein levels are presented. Expression levels were normalized to -Actin 
expression as the internal control and represented as relative values to those of CD41
−
 cells. 
Quantification was performed by ImageJ software. Error bars indicate SD (n = 5; **P 
< .01, Student t test). 
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Figure 21. THPO upregulates BCL-xL expression in Evi1 leukemia cells. 
Cryopreserved BM- or SP-MNCs from Evi1 leukemia mice were thawed and 
serum-starved in -MEM containing 1% BSA for 3 hours, and then stimulated with or 
without THPO in -MEM containing 0.1% BSA for 7 hours. Cells were washed with PBS 
and lysed for protein extraction. The expression levels of BCL-xL (A), BCL-2 (B), and 
MCL-1 (C) were determined by western blotting. Representative images and bar graphs 
showing quantified protein levels are presented. Quantification was performed as 
described in Figure 20. Error bars indicate SD (n = 4; *P < .05, Student t test). 
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Figure 22. Pharmacologic inhibition of BCL-xL suppresses proliferation and induces 
apoptosis of CD41
+
 Evi1 leukemia cells cultured on OP9 stromal cells. 
CD41
+
 or CD41
− 
cells were treated with DMSO as a vehicle control or a BCL-xL inhibitor 
(WEHI-539; 0.2, 0.4, and 0.8 M) on OP9 stromal cells in the presence of THPO for 7 
days. (A) The number of viable cells was counted. Error bars indicate SD (n = 3). (B) The 
rate of apoptotic cells was determined by FACS. Error bars indicate SD (n = 3). Black and 
white bars represent the results from CD41
+
 and CD41
− 
cells, respectively. There was no 
significant difference between DMSO- and WEHI-539-treated groups (Dunnett’s test). 
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CD41 is expressed in BM-MNCs derived from primary AML patients with EVI1 
expression 
Several clinical studies reported that CD41 or CD61 expression is detected by FACS or 
immunohistochemistry in a subset of AML specimens with 3q abnormalities.
40-44
 
Therefore, I finally examined CD41 expression by FACS using 4 primary AML samples, 
one carrying a t(3;3) translocation and the others carrying an MLL-rearrangement (Table 4). 
Among them, CD34
+
 cells derived from the t(3;3) patient and 1 MLL-rearranged patient 
more frequently expressed CD41 than those from the others (Figure 23A). Interestingly, 
CD34
+
 cells of these 2 patients clearly expressed EVI1 (Figure 23B–C). These results 
indicate that CD41 upregulation is also found in primary AML samples with EVI1 
expression, although further investigation using more clinical samples will be needed to 
confirm the relationship between EVI1 and CD41. 
 
 
 
 
 
 
 
58 
 
Table 4. Clinical characteristics of the 4 patients with AML 
 
Patient 
No. 
Age Sex Disease status Type Cytogenetics 
Blast 
(%) 
1 33 F Relapse 1 AML-MRC 
46, XX, t(3;3)(q21;q26.2), 
der(11)add(11)(p11.2)add(11)(q21), 
inv(11)(p15q13) 
51 
2 68 F Onset AML (M5a) 46, XX, t(6;11)(q27;q23) 97 
3 48 M Induction failure AML (M4) 46, XY, t(11;19)(q23;p13.1)  5 
4 42 F Induction failure AML (M4) 46, XX, t(9;11)(p22;q23)  12.5 
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Figure 23. EVI1 expression in CD34
+
/CD41
+
 cells derived from AML patients. 
(A) BM-MNCs derived from 4 AML patients, one carrying a t(3;3) translocation (Patient 
1) and the others carrying an MLL-rearrangement (Patient 2–4), were analyzed by FACS. 
Frequencies of CD41
+
 cells within CD34
+
, CD34
+
/CD38
−
, or CD34
+
/CD38
+ 
fraction are 
presented. (B) For qPCR analysis, subfractions were sorted as follows: CD34
+
/CD41
+
 (I) 
and CD34
+
/CD41
−
 (II) for patient 1, 3, and 4; CD34
+
/CD38
−
/CD41
+
 (I), 
CD34
+
/CD38
−
/CD41
−
 (II), CD34
+
/CD38
+
/CD41
+
 (III), and CD34
+
/CD38
+
/CD41
−
 (IV) for 
patient 2. 
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Figure 23. EVI1 expression in CD34
+
/CD41
+
 cells derived from AML patients. 
(continued) 
(C) EVI1 expression was analyzed by qPCR in subfractions of primary AML cells shown 
in panel B, and EVI1
+
 (HEL, KU812, and K562) and EVI1
−
 (HL60 and MOLM13) cell 
lines. Expression levels relative to K562 cells are presented. ND means not detected. 
Clinical characteristics of the patients are presented in Table 4. 
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Discussion 
In this study, I found that the expression of ITGA2B and MPL positively correlated with 
that of EVI1 in AML patients and that a subfraction of BM and SP cells derived from Evi1 
leukemia mice expressed both CD41 and Mpl. Several lines of evidence demonstrated that 
CD41
+
 Evi1 leukemia cells not only contain immunophenotypically and functionally more 
immature cells but also exert a higher LIC in serial transplantation assays than CD41
−
 cells. 
Moreover, the fact that THPO/MPL signaling supported the growth and survival of CD41
+
 
cells via upregulation of BCL-xL provides the novel molecular pathogenesis of Evi1 
leukemia (Figure 24). 
It has been shown that the THPO/MPL pathway is involved in leukemogenesis as 
well as megakaryopoiesis.
45
 According to studies using primary AML samples, Mpl is 
expressed in 50% to 60% of AML cases,
46-49
 and the majority of AML myeloblasts 
expressing Mpl proliferate in vitro in response to THPO.
46,47
 In addition, inappropriately 
low levels of serum-circulating THPO, which recovered after effective chemotherapy, 
were reported in Mpl
+
 AML patients, indicating that THPO is bound to Mpl
+
 leukemia 
cells to promote their growth in vivo.
50
 Recent reports that Mpl expression is upregulated 
in human AML cells harboring chromosomal translocation t(8;21)(q22;q22), which 
generates the AML1-ETO fusion gene, and THPO enhances their growth and self-renewing 
capacity further explain the biological relevance of this pathway in leukemogenesis.
51,52 
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Figure 24. THPO/MPL signaling enhances growth and survival capacity of CD41
+
 
Evi1 leukemia cells. 
Evi1 transduction in immature murine hematopoietic cells gives rise to CD41
+
/Mpl
+
 
leukemia cells with a high LIC in vivo. THPO stimulation leads to phosphorylation of 
downstream pathways such as JAK/STAT and MEK/ERK, and upregulation of BCL-xL, 
which confers growth and survival capacity to CD41
+
 Evi1 leukemia cells. It is still 
unclear whether Evi1 directly regulates Itga2b and Mpl expression and whether CD41 
signaling is involved in leukemogenesis. 
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Here, I propose that THPO/MPL signaling is also implicated in the pathogenesis 
of Evi1-overexpressing AML that is clinically and molecularly distinct from 
AML1-ETO-positive AML, thus reinforcing the biological relevance of this pathway in 
leukemogenesis. Interestingly, there are some differences and similarities regarding the 
downstream cascades of the THPO/MPL pathway between Evi1 and AML1-ETO AML 
cells. In AML1-ETO leukemia models, the JAK/STAT and PI3K/AKT pathways rather 
than the MEK/ERK pathway are the important downstream cascades of THPO/MPL 
signaling.
51,52
 In contrast, all 3 pathways were involved in the growth and survival of Evi1 
leukemia cells, even though AKT activation was not induced by THPO (Figure 16A). 
Because Evi1 activates PI3K/AKT signaling by downregulating PTEN,
17
 PTEN repression 
may have a predominant effect on AKT activation under the Evi1-overexpressed condition, 
compared with MPL-mediated activation of AKT. These findings indicate that the 
regulation of molecular networks downstream of MPL signaling varies in different cellular 
contexts. Here, I also demonstrated that BCL-xL expression was enhanced in CD41
+
 Evi1 
leukemia cells upon THPO stimulation and that pharmacologic inhibition of BCL-xL 
suppressed their growth and survival in vitro. Importantly, upregulation of BCL-xL 
through THPO/MPL signaling plays an essential role in sustaining the viability of normal 
megakaryocytes and leukemia cells carrying t(8;21)(q22;q22).
45,51,53
 Therefore, I suppose 
that the THPO/MPL/BCL-xL cascade may serve as a common oncogenic driver for Mpl
+
 
64 
 
AML cases irrespective of the cytogenetic or prognostic subclasses of AML. Although 
Table 1 implies the possible relevance of BCL-2 with Evi1-related leukemogenesis, it is 
unclear whether BCL-2 is also important for the survival of Evi1 leukemia cells. Because 
BCL-2 protein expression was not induced by THPO stimulation (Figure 21B), other 
mechanisms might regulate BCL-2 expression in Evi1-overexpressing cells. On the other 
hand, BCL-xL gene was not found in Table 1. There are 2 possible reasons for this. One 
reason is that BCL-xL upregulation is not a specific feature of EVI1-high AML, because 
BCL-xL expression is positively correlated with a cluster of EVI1-negative AML such as 
AML with the chromosomal translocation t(8;21)(q22;q22) as described above. The other 
reason is that BCL-xL expression might relatively depend on post-translational regulation. 
A previous report demonstrating that THPO/MPL signaling prevents the cleavage of 
BCL-xL protein during normal megakaryopoiesis supports this speculation.
53 
In contrast, 
Pradhan et al. recently reported that EVI1 directly induces BCL-xL expression through its 
binding to a BCL-xL promoter region in HT-29 colon carcinoma cells that express EVI1.
54
 
However, it is still unknown whether BCL-xL gene is a direct transcriptional target of EVI1 
in human AML patients’ cells. 
While THPO/MPL signaling clearly enhanced the growth and survival of CD41
+
 
Evi1 leukemia cells, several experimental results presented in this study indicate that 
Evi1-related leukemogenesis may not completely depend on the THPO/MPL pathway. 
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Firstly, the THPO/MPL pathway seems to be dispensable for the growth of Evi1 leukemia 
cells in the semisolid culture system, because MethoCult M3434 medium does not contain 
THPO (Figure 8A). Moreover, addition of THPO to M3434 did not enhance the 
colony-forming activity of CD41
+
 or CD41
−
 cells (data not shown), raising the possibility 
that dependence on THPO/MPL signaling of Evi1 leukemia cells is reduced under 
semisolid culture conditions. The observation that Mpl expression on Evi1 leukemia cells 
was not maintained in M3434 culture (data not shown) may support this idea. Secondly, 
CD41
−
 cells moderately possessed a LIC, because half of the mice transplanted with 
CD41
−
 cells died from AML after a longer latency period than that in mice transplanted 
with CD41
+
 cells (Figure 9). Furthermore, the limiting dilution transplantation assay 
revealed that in addition to CD41
+
 fractions (Fr.1 and Fr.2), CD41
−
/CD150
+
 cells (Fr.3) 
also exhibited a high LIC (Figure 11B). Although Fr.3 might respond to THPO in vivo 
because Mpl expression in Fr.3 was significantly higher than that in CD41
−
/CD150
−
 cells 
(Fr.4) (data not shown), further experiments are required to uncover the molecular 
mechanism(s) that confer such a strong LIC to leukemia cells in Fr.3. For example, 
comprehensive gene expression analyses such as microarrays and high-throughput mRNA 
sequencing (RNA-Seq) could provide mechanistic insights into how each fraction exerts 
their leukemic properties. 
Throughout the study, CD41 served as a surrogate marker for Mpl
+
 Evi1 leukemia 
66 
 
cells. However, it is yet unclear whether CD41 signaling is responsible for the growth and 
survival of Evi1 leukemia cells. In megakaryocytes and platelets, CD41 and CD61 form a 
heterodimer and function as a receptor for several extracellular matrices such as 
fibronectin, vitronectin, and fibrinogen. For example, fibrinogen localized at vascular 
sinusoids in BM stimulates megakaryocytes through CD41/CD61 to induce proplatelet 
formation.
55
 MWReg30, which was used here as an anti-mouse CD41 antibody, is known 
to block the function of CD41 on platelets and megakaryocytes.
55,56
 Gekas and Graf
57
 
reported that MWReg30-treated murine HSCs show impaired long-term repopulation 
ability in vivo, suggesting that CD41/CD61 signaling is involved in the homing and 
lodging of normal HSCs in BM. However, I could not obtain clear evidence that 
CD41/CD61 is crucial for Evi1-mediated leukemogenesis, because CD41
+
 cells stained 
with MWReg30 retained the capacity to induce secondary leukemia, and showed homing 
capacity to the BM and SP that was equivalent to that of CD41
−
 cells (Figure 10). In 
addition, I found that the progression of AML was not delayed when Evi1 leukemia cells 
in which surface CD41 expression was partially interfered by an Itga2b-knockdown vector 
were transplanted into mice (data not shown). Thus, CD41/CD61 signaling might be 
dispensable for the proliferation or homing of Evi1 leukemia cells in vivo. 
I found here that the expression of ITGA2B and MPL positively correlated with 
that of EVI1 in AML patients and that overexpression of Evi1 in mouse BM cells gave rise 
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to CD41
+
 and Mpl
+
 leukemia cells. However, it is not clear how Evi1 induces the 
expression of megakaryocytic marker genes. One possibility is that Evi1 directly 
upregulates Itga2b and Mpl gene expression. However, there are no reports so far 
suggesting that these genes are the direct transcriptional targets of Evi1. Two groups have 
recently published the chromatin immunoprecipitation sequencing (ChIP-Seq) data of 
human ovarian carcinoma cell lines transduced with human EVI1
58
 and that of 
Evi1-expressing murine leukemia cell lines.
59
 In the human ovarian carcinoma cell dataset, 
1 Evi1-bound peak was found in the MPL gene locus between exons 10 and 11. In the 
murine leukemia cell dataset, 1 Evi1-bound peak and 2 Evi1-bound peaks were found in 
estimated promoter regions of Mpl and Itga2b gene, respectively. These results raise a 
possibility that Evi1 could directly bind to these loci to activate gene expression via 
unidentified transcriptional machineries. Interestingly, 6 Evi1-bound peaks and 1 
Evi1-bound peak were detected in the BCL-xL (BCL2L1) gene locus in the human and 
murine datasets, respectively, thus speculating some relevance of Evi1 in BCL-xL gene 
regulation. Alternatively, Evi1 may regulate the expression of key transcription factor(s) or 
physically interact with various epigenetic modifiers to increase ITGA2B and MPL 
expression. Recently, the existence of a distinct HSC subset biased toward the generation 
of CD41
+
 megakaryocyte progenitors, whose maintenance depends on THPO, was 
reported.
60
 Accordingly, Evi1 transduction might deregulate the epigenetic status of 
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HSPCs to render them partly similar to such a platelet-biased HSC fraction, resulting in 
increased generation of CD41
+
/Mpl
+
 transformed cells. 
With regard to Mpl induction, it is still controversial whether Evi1 upregulates or 
downregulates Mpl expression. In our AML mouse model, Mpl was clearly expressed in 
Evi1 leukemia cells at both the mRNA and protein levels (Figure 12). On the contrary, Mpl 
expression decreases in hematopoietic cells from another mouse model in which 
transduction of human EVI1 gene causes myelodysplastic syndrome (MDS).
61
 In this 
model, EVI1 physically interacts with Gata1 to suppress the transcription of Mpl and the 
erythropoietin receptor, Epor.
20,62
 One of the major differences between these mouse 
models is the species of the Evi1 gene used, that is, human EVI1 and mouse Evi1 were 
used for the induction of MDS and AML, respectively. Laricchia-Robbio et al. proved that 
the proximal zinc finger domain (especially the first and sixth zinc fingers) of human EVI1 
is crucial for direct interaction with Gata1.
20
 Although mouse Evi1 used in this study also 
possesses a putative proximal zinc-finger domain equivalent to that of human EVI1, it is as 
yet unclear whether mouse Evi1 can repress Gata1 function through protein-protein 
interactions. From the perspective of Gata1 gene expression, Gata1 expression was 
upregulated in Evi1 leukemia BM cells, compared with that in normal c-kit
+
 BM cells 
(data not shown). Given the fact that the transcription of Gata1 is positively regulated by 
Gata1 itself,
63
 it is unlikely that Gata1 is counteracted by Evi1 in our mouse model. 
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However, I cannot exclude the possibility that expression of Mpl and Gata1 is controlled in 
a disease-stage-specific manner during the process of developing Evi1 leukemia. As shown 
in Figure 9, leukemic symptoms emerged after a relatively longer latency (over 150 days) 
in transplantation assays, suggesting that the disease phenotype at earlier time points after 
transplantation may be different from that observed in the later leukemic stage. Therefore, 
monitoring of Gata1 and Mpl expression along with disease progression will help elucidate 
how their expression is regulated in the context of Evi1-overexpression. 
For further confirming the importance of THPO/MPL signaling in Evi1-related 
AML, experiments using a number of EVI1
+
 AML patients’ specimens are required. 
Although I show here that CD41
+
 HSPC fractions were found in 2 EVI1
+
 AML patients’ 
BM cells by FACS, I did not investigate whether these cells co-expressed MPL or whether 
THPO stimulation enhanced their growth and survival capacity. Thus, in the future, a 
variety of EVI1
+
 AML BM cells might enable examining the correlation among EVI1, 
CD41, MPL, and BCL-xL at both mRNA and protein levels and identification of whether 
THPO modulates the leukemogenic property of EVI1
+
 AML cells in biological assays as 
performed in this study. In addition, the surface CD41 expression in a subset of EVI1
+
 
AML cells is quite interesting in terms of AML diagnosis. Acute megakaryoblastic 
leukemia is a rare subtype of acute myeloid leukemia and is recognized as subtype 
AML-M7, within the French-American-British classification. Because one of the 
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hallmarks of AML-M7 is marked expression of megakaryocytic markers such as CD41 
and CD61, one might think that CD41
+
/EVI1
+
 AML cases as exemplified in this study are 
classified as AML-M7. However, these cases were not diagnosed as AML-M7 (Table 4), 
partly due to the absence of megakaryoblastic features in their morphology. Therefore, 
abnormal CD41 expression can be observed in AML cases other than AML-M7, which 
might include those with high EVI1 expression. 
Finally, I mention the future therapies for EVI1
+
 AML. As described, deregulated 
expression of Evi1 drives multiple oncogenic pathways in hematopoietic cells, which may 
account for the extremely poor therapeutic responses to conventional chemotherapy. 
Molecular targeted therapy is one of the most promising strategies for eradicating EVI1
+
 
leukemia cells. A previous report has suggested that rapamycin, an mTOR inhibitor, 
significantly prolongs the survival of Evi1 leukemia mice.
17
 Morishita’s group has proven 
the efficacy of neutralizing antibodies targeting the cell-to-niche interactions. For example, 
a neutralizing antibody against ITGA6 reduces the cell adhesion ability of EVI1
+
 AML 
cells and renders them vulnerable to anti-cancer drugs.
29
 More recently, all-trans retinoic 
acid (ATRA) was reported to reduce the clonogenic capacity of EVI1
+
 AML cells both in 
vitro and in vivo by inducing their differentiation.
64
 Here, I show that targeting the 
THPO/MPL/BCL-xL cascade might have beneficial effects on suppressing the LIC of 
Evi1-expressing leukemia cells. Based on these findings, combination therapies targeting 
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the downstream pathways of oncogenic EVI1 could be developed for treating EVI1
+
 AML 
patients. Another possible therapy is to target EVI1 itself. Because EVI1 overexpression 
activates various undesirable oncogenic programs to form highly refractory AML, it might 
become a reasonable therapy to reduce EVI1 expression to normal or undetectable levels. 
One example is the report that a specific microRNA, miR-133, that can bind to the 3′ 
untranslated region of EVI1 antagonizes EVI1 expression to induce chemo-sensitivity in 
EVI1
+
 AML cell lines.
65
 The machinery for EVI1 transactivation might also become an 
ideal therapeutic target. Two recent reports have proven that juxtaposition of a distal 
GATA2 enhancer with the EVI1 gene locus that is caused by 3q chromosomal 
rearrangements, leads to deregulated EVI1 expression.
66,67
 Importantly, genomic excision 
of the enhancer or treatment with a BET-bromodomain inhibitor results in EVI1 reduction, 
leading to growth inhibition and differentiation of EVI1
+
 AML cell lines. Thus, these 
pioneering studies provide a rationale for antagonizing EVI1 expression in EVI1-related 
AML treatment in the future. 
In conclusion, I revealed in this study that THPO/MPL signaling enhances the 
growth and survival of CD41
+
 cells in a mouse model of Evi1 leukemia. These findings 
suggest the novel molecular mechanism of Evi1 leukemia through which Evi1 leukemia 
cells expressing Mpl may acquire growth and survival capacity by employing THPO as a 
cell-extrinsic factor. Accumulating discoveries regarding Evi1 functions have suggested 
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that the global epigenetic perturbations caused by Evi1 and the recently identified 
Evi1-related interactome
68
 can drive multiple oncogenic molecular pathways, finally 
leading to AML development and maintenance. Although further investigations are needed 
to clarify how the expression of Mpl and other several megakaryocyte/platelet-related 
genes is regulated in the context of Evi1-overexpression, the present study provides 
insights into the pleiotropic roles of Evi1 in leukemogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
Acknowledgments 
I would like to express my sincere gratitude to Professor Mineo Kurokawa for his patient 
guidance and continuous encouragement throughout this study. I would like to offer 
special thanks to Dr. Shunya Arai for his helpful advice, suggestions, and technical 
guidance. I also would like to express my deepest gratitude to Dr. Naoko 
Watanabe-Okochi for providing me with valuable experimental tools and her kind 
cooperation. 
I would like to extend my sincere gratitude to Dr. Yosuke Masamoto, Dr. Yuki 
Kagoya, and Dr. Takashi Toya for their helpful supports and valuable comments. I am also 
profoundly grateful to Ms. Yoshi Shimamura, Ms. Fumi Kaminaga, Ms. Mariko Yamamoto, 
Ms. Mayumi Kobayashi, the late Ms. Yuko Sawamoto, and all members of Professor 
Kurokawa’s Laboratory for their excellent technical supports and valuable comments. 
I would like to thank Dr. Hiroshi Miyazaki and many researchers of Kyowa 
Hakko Kirin Co., Ltd. for their constant encouragement. 
Finally, I would like to thank my wife for her understanding, sincere 
encouragement, and continuing supports throughout my study. 
 
 
 
74 
 
References 
1. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid 
leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-486. 
2. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, 
Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, 
Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, 
Delwel R. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study 
of 319 de novo AML patients. Blood. 2003;101(3):837-845. 
3. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van 
Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, 
Löwenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid 
leukemia. N Engl J Med. 2004;350(16):1617-1628. 
4. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, 
Beverloo HB, Löwenberg B, Delwel R. High EVI1 levels predict adverse outcome in acute 
myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 
abnormalities underestimated. Blood. 2008;111(8):4329-4337. 
5. Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van 
Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, 
Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner 
75 
 
K, Delwel R. High EVI1 expression predicts outcome in younger adult patients with acute 
myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 
2010;28(12):2101-2107. 
6. Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, 
Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, 
Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von 
Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, 
Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H. Clinical, 
molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) 
and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 
2010;28(24):3890-3898. 
7. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, 
Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 
4th ed. Lyon, France: International Agency for Research on Cancer Press; 2008. 
8. Kataoka K, Kurokawa M. Ecotropic viral integration site 1, stem cell self-renewal 
and leukemogenesis. Cancer Sci. 2012;103(8):1371-1377. 
9. Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de 
Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, Stary J, Trka J, Zimmermann 
M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM. EVI1 
76 
 
overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 
2010;24(5):942-949. 
10. Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe 
K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, 
Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S. EVI1 
overexpression is a poor prognostic factor in pediatric patients with mixed lineage 
leukemia-AF9 rearranged acute myeloid leukemia. Haematologica. 2014;99(11):e225-227. 
11. Jo A, Mitani S, Shiba N, Hayashi Y, Hara Y, Takahashi H, Tsukimoto I, Tawa A, 
Horibe K, Tomizawa D, Taga T, Adachi S, Yoshida T, Ichikawa H. High expression of 
EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia. 
2015;29(5):1076-1083. 
12. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, 
Suda T, Morishita K. Oncogenic transcription factor Evi1 regulates hematopoietic stem 
cell proliferation through GATA-2 expression. EMBO J. 2005;24(11):1976-1987. 
13. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, Chiba S, 
Kurokawa M. Evi-1 is a critical regulator for hematopoietic stem cells and transformed 
leukemic cells. Cell Stem Cell. 2008;3(2):207-220. 
14. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, 
Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota N, Kadowaki T, Kurokawa 
77 
 
M. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks 
hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 
2011;208(12):2403-2416. 
15. Sato T, Goyama S, Nitta E, Takeshita M, Yoshimi M, Nakagawa M, Kawazu M, 
Ichikawa M, Kurokawa M. Evi-1 promotes para-aortic splanchnopleural hematopoiesis 
through up-regulation of GATA-2 and repression of TGF-b signaling. Cancer Sci. 
2008;99(7):1407-1413. 
16. Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y, 
Kurokawa M. Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and 
leukemic cells. Oncogene. 2009;28(49):4364-4374. 
17. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai 
S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, Kurokawa M. Evi1 represses 
PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. 
Blood. 2011;117(13):3617-3628. 
18. Senyuk V, Sinha KK, Li D, Rinaldi CR, Yanamandra S, Nucifora G. Repression of 
RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis. Cancer Res. 
2007;67(12):5658-5666. 
19. Laricchia-Robbio L, Premanand K, Rinaldi CR, Nucifora G. EVI1 Impairs 
myelopoiesis by deregulation of PU.1 function. Cancer Res. 2009;69(4):1633-1642. 
78 
 
20. Laricchia-Robbio L, Fazzina R, Li D, Rinaldi CR, Sinha KK, Chakraborty S, 
Nucifora G. Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and 
allow erythroid differentiation of murine bone marrow cells. Mol Cell Biol. 
2006;26(20):7658-7666. 
21. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, 
Matsumoto K, Hirai H. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting 
Smad3. Nature. 1998;394(6688):92-96. 
22. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, 
Moriguchi T, Nishida E, Yazaki Y, Hirai H. The evi-1 oncoprotein inhibits c-Jun 
N-terminal kinase and prevents stress-induced cell death. EMBO J. 
2000;19(12):2958-2968. 
23. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor 
CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood. 
2001;97(9):2815-2822. 
24. Vinatzer U, Taplick J, Seiser C, Fonatsch C, Wieser R. The leukaemia-associated 
transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone 
deacetylase. Br J Haematol. 2001;114(3):566-573. 
25. Goyama S, Nitta E, Yoshino T, Kako S, Watanabe-Okochi N, Shimabe M, Imai Y, 
Takahashi K, Kurokawa M. EVI-1 interacts with histone methyltransferases SUV39H1 
79 
 
and G9a for transcriptional repression and bone marrow immortalization. Leukemia. 
2010;24(1):81-88. 
26. Senyuk V, Premanand K, Xu P, Qian Z, Nucifora G. The oncoprotein EVI1 and 
the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of 
target DNA. PLoS One. 2011;6(6):e20793. 
27. Chakraborty S, Senyuk V, Sitailo S, Chi Y, Nucifora G. Interaction of EVI1 with 
cAMP-responsive element-binding protein-binding protein (CBP) and 
p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in 
co-localization in nuclear speckles. J Biol Chem. 2001;276(48):44936-44943. 
28. Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita 
K. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with 
high EVI1 expression. Leukemia. 2011;25(6):921-931. 
29. Yamakawa N, Kaneda K, Saito Y, Ichihara E, Morishita K. The increased 
expression of integrin alpha6 (ITGA6) enhances drug resistance in EVI1(high) leukemia. 
PLoS One. 2012;7(1):e30706. 
30. Saito Y, Kaneda K, Suekane A, Ichihara E, Nakahata S, Yamakawa N, Nagai K, 
Mizuno N, Kogawa K, Miura I, Itoh H, Morishita K. Maintenance of the hematopoietic 
stem cell pool in bone marrow niches by EVI1-regulated GPR56. Leukemia. 
2013;27(8):1637-1649. 
80 
 
31. Watanabe-Okochi N, Yoshimi A, Sato T, Ikeda T, Kumano K, Taoka K, Satoh Y, 
Shinohara A, Tsuruta T, Masuda A, Yokota H, Yatomi Y, Takahashi K, Kitaura J, 
Kitamura T, Kurokawa M. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), 
collaborates with Evi1 to induce AML in a mouse BMT model. Blood. 
2013;121(20):4142-4155. 
32. Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, 
Kurokawa M. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in 
hematopoietic stem cells. Blood. 2011;117(23):6304-6314. 
33. Kagoya Y, Yoshimi A, Kataoka K, Nakagawa M, Kumano K, Arai S, Kobayashi 
H, Saito T, Iwakura Y, Kurokawa M. Positive feedback between NF-κB and TNF-α 
promotes leukemia-initiating cell capacity. J Clin Invest. 2014;124(2):528-542. 
34. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, Kumagai H. 
Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional 
genomics. Exp Hematol. 2003;31(11):1007-1014. 
35. Verhaak RG, Wouters BJ, Erpelinck CA, Abbas S, Beverloo HB, Lugthart S, 
Löwenberg B, Delwel R, Valk PJ. Prediction of molecular subtypes in acute myeloid 
leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134. 
36. Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher 
MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, 
81 
 
Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri 
MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield 
CD, Rowley JD, Bohlander SK, Chen J. Identification of a 24-gene prognostic signature 
that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an 
international collaborative study. J Clin Oncol. 2013;31(9):1172-1181. 
37. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Månsson R, Thoren 
LA, Ekblom M, Alexander WS, Jacobsen SE. Critical role of thrombopoietin in 
maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6):671-684. 
38. Yoshihara H, Arai F, Hosokawa K, Hagiwara T, Takubo K, Nakamura Y, Gomei 
Y, Iwasaki H, Matsuoka S, Miyamoto K, Miyazaki H, Takahashi T, Suda T. 
Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and 
interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-697. 
39. Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, Baell JB, 
Colman PM, Deshayes K, Fairbrother WJ, Flygare JA, Gibbons P, Kersten WJ, 
Kulasegaram S, Moss RM, Parisot JP, Smith BJ, Street IP, Yang H, Huang DC, Watson 
KG. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 
2013;9(6):390-397. 
40. Ohyashiki JH, Ohyashiki K, Shimamoto T, Kawakubo K, Fujimura T, Nakazawa 
S, Toyama K. Ecotropic virus integration site-1 gene preferentially expressed in 
82 
 
post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, 
and stem cell leukemia gene expression. Blood. 1995;85(12):3713-3718. 
41. Shi G, Weh HJ, Duhrsen U, Zeller W, Hossfeld DK. Chromosomal abnormality 
inv(3)(q21q26) associated with multilineage hematopoietic progenitor cells in 
hematopoietic malignancies. Cancer Genet Cytogenet. 1997;96(1):58-63. 
42. Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, Kogel KE, 
Azar CA, Patel S, Alizadeh AA. Immunophenotypic features of acute myeloid leukemia 
with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Leuk Res. 2010;34(5):594-597. 
43. Yamamoto K, Okamura A, Sanada Y, Yakushijin K, Matsuoka H, Minami H. 
Marked thrombocytosis and dysmegakaryopoiesis in acute myeloid leukemia with 
t(2;3)(p22;q26.2) and EVI1 rearrangement. Ann Hematol. 2013;92(12):1713-1715. 
44. Danilova OV, Levy NB, Kaur P. A case report of AML with 
myelodysplasia-related changes with aggressive course in association with t(3;8)(q26;q24). 
J Hematopathol. 2013;6(4):245–251. 
45. Chou FS, Mulloy JC. The thrombopoietin/MPL pathway in hematopoiesis and 
leukemogenesis. J Cell Biochem. 2011;112(6):1491-1498. 
46. Matsumura I, Kanakura Y, Kato T, Ikeda H, Ishikawa J, Horikawa Y, Hashimoto 
K, Moriyama Y, Tsujimura T, Nishiura T. Growth response of acute myeloblastic 
leukemia cells to recombinant human thrombopoietin. Blood. 1995;86(2):703-709. 
83 
 
47. Quentmeier H, Zaborski M, Graf G, Ludwig WD, Drexler HG. Expression of the 
receptor MPL and proliferative effects of its ligand thrombopoietin on human leukemia 
cells. Leukemia. 1996;10(2):297-310. 
48. Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrózek 
K, Block AW, Herzig GP, Bloomfield CD. Expression of c-mpl mRNA, the receptor for 
thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor 
response to intensive chemotherapy. J Clin Oncol. 1997;15(6):2262-2268. 
49. Takeshita A, Shinjo K, Izumi M, Ling P, Nakamura S, Naito K, Ohnishi K, Ohno 
R. Quantitative expression of thrombopoietin receptor on leukaemia cells from patients 
with acute myeloid leukaemia and acute lymphoblastic leukaemia. Br J Haematol. 
1998;100(2):283-290. 
50. Corazza F, Hermans C, D'Hondt S, Ferster A, Kentos A, Benoît Y, Sariban E. 
Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid 
leukemia. Blood. 2006;107(6):2525-2530. 
51. Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, 
Mizukawa B, Shen S, Marcucci G, Mulloy JC. The thrombopoietin/MPL/Bcl-xL pathway 
is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. 
Blood. 2012;120(4):709-719. 
52. Pulikkan JA, Madera D, Xue L, Bradley P, Landrette SF, Kuo YH, Abbas S, Zhu 
84 
 
LJ, Valk P, Castilla LH. Thrombopoietin/MPL participates in initiating and maintaining 
RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling. Blood. 
2012;120(4):868-879. 
53. Kozuma Y, Kojima H, Yuki S, Suzuki H, Nagasawa T. Continuous expression of 
Bcl-xL protein during megakaryopoiesis is post-translationally regulated by 
thrombopoietin-mediated Akt activation, which prevents the cleavage of Bcl-xL. J Thromb 
Haemost. 2007;5(6):1274-1282. 
54. Pradhan AK, Mohapatra AD, Nayak KB, Chakraborty S. Acetylation of the 
proto-oncogene EVI1 abrogates Bcl-xL promoter binding and induces apoptosis. PLoS 
One. 2011;6(9):e25370. 
55. Larson MK, Watson SP. Regulation of proplatelet formation and platelet release 
by integrin alpha IIb beta3. Blood. 2006;108(5):1509-1514. 
56. Nieswandt B, Echtenacher B, Wachs FP, Schröder J, Gessner JE, Schmidt RE, 
Grau GE, Männel DN. Acute systemic reaction and lung alterations induced by an 
antiplatelet integrin gpIIb/IIIa antibody in mice. Blood. 1999;94(2):684-693. 
57. Gekas C, Graf T. CD41 expression marks myeloid-biased adult hematopoietic 
stem cells and increases with age. Blood. 2013;121(22):4463-4472. 
58. Bard-Chapeau EA, Jeyakani J, Kok CH, Muller J, Chua BQ, Gunaratne J, 
Batagov A, Jenjaroenpun P, Kuznetsov VA, Wei CL, D'Andrea RJ, Bourque G, Jenkins 
85 
 
NA, Copeland NG. Ecotopic viral integration site 1 (EVI1) regulates multiple cellular 
processes important for cancer and is a synergistic partner for FOS protein in invasive 
tumors. Proc Natl Acad Sci U S A. 2012;109(6):2168-2173. 
59 Glass C, Wuertzer C, Cui X, Bi Y, Davuluri R, Xiao YY, Wilson M, Owens K, 
Zhang Y, Perkins A. Global Identification of EVI1 Target Genes in Acute Myeloid 
Leukemia. PLoS One. 2013;8(6):e67134. 
60. Sanjuan-Pla A, Macaulay IC, Jensen CT, Woll PS, Luis TC, Mead A, Moore S, 
Carella C, Matsuoka S, Bouriez Jones T, Chowdhury O, Stenson L, Lutteropp M, Green 
JC, Facchini R, Boukarabila H, Grover A, Gambardella A, Thongjuea S, Carrelha J, 
Tarrant P, Atkinson D, Clark SA, Nerlov C, Jacobsen SE. Platelet-biased stem cells reside 
at the apex of the haematopoietic stem-cell hierarchy. Nature. 2013;502(7470):232-236. 
61. Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, Ni H, Saunthararajah Y, 
Nucifora G. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest. 
2004;114(5):713-719. 
62. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F, 
Fazzina R, Nucifora G. Methylation and silencing of miRNA-124 by EVI1 and 
self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. 
Proc Natl Acad Sci U S A. 2010;107(21):9783-9788. 
63. Tsai SF, Strauss E, Orkin SH. Functional analysis and in vivo footprinting 
86 
 
implicate the erythroid transcription factor GATA-1 as a positive regulator of its own 
promoter. Genes Dev. 1991;5(6):919-931. 
64 Verhagen HJ, Smit MA, Rutten A, Denkers F, Poddighe PJ, Merle PA, 
Ossenkoppele GJ, Smit L. Primary acute myeloid leukemia cells with overexpression of 
EVI-1 are sensitive to all-trans retinoic acid. Blood. 2016;127(4):458-463. 
65 Yamamoto H, Lu J, Oba S, Kawamata T, Yoshimi A, Kurosaki N, Yokoyama K, 
Matsushita H, Kurokawa M, Tojo A, Ando K, Morishita K, Katagiri K, Kotani A. 
miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target. Sci Rep. 
2016;6:19204. 
66 Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck 
C, van der Velden VH, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, 
Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJ, Bindels EM, de 
Laat W, Delwel R. A single oncogenic enhancer rearrangement causes concomitant EVI1 
and GATA2 deregulation in leukemia. Cell. 2014;157(2):369-381. 
67 Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, 
Yamamoto M. A remote GATA2 hematopoietic enhancer drives leukemogenesis in 
inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25(4):415-427. 
68. Bard-Chapeau EA, Gunaratne J, Kumar P, Chua BQ, Muller J, Bard FA, 
Blackstock W, Copeland NG, Jenkins NA. EVI1 oncoprotein interacts with a large and 
87 
 
complex network of proteins and integrates signals through protein phosphorylation. Proc 
Natl Acad Sci U S A. 2013;110(31):E2885-2894. 
